Drugs / KS101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07143331 | Aug 2025 → Apr 2026 overdue | Alzheimer disease, chronic kidney disease | Klotho Sciences Australia Pty Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KS101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07143331 ↗ |
| Route | Oral | “following the oral administration of single and multiple ascending doses of KS101 in healthy participants” NCT07143331 ↗ |